{"version":"1.0","type":"rich","provider_name":"Acast","provider_url":"https://acast.com","height":250,"width":700,"html":"<iframe src=\"https://embed.acast.com/$/5b0fd1107b67904376d520f7/636cd83cc8920300134d7566?\" frameBorder=\"0\" width=\"700\" height=\"250\"></iframe>","title":"AstraZeneca, Market Catalysts and a NASDAQ IPO with Alan Green","thumbnail_width":200,"thumbnail_height":200,"thumbnail_url":"https://open-images.acast.com/shows/5b0fd1107b67904376d520f7/1528450062858-bed092fdeb27e812728e9e7b55a3d7a5.jpeg?height=200","description":"<p>Alan Green joins the Podcast as we delve into key markets theme and a number of UK equities.</p><p><br></p><p>We discuss:</p><p><br></p><p><strong>AstraZeneca (LON:AZN)</strong></p><p><strong>Georgia Capital (LON:CGEO)</strong></p><p><strong>Vela Technologies (LON:VELA)</strong></p><p><br></p><p>We start by looking at potential catalysts for markets as we move into the winter.</p><p><br></p><p>AstraZeneca has reported a solid set of third quarter results as the company sees the benefits of higher cancer drug sales.</p><p><br></p><p>Georgia Capital has been trading at deep discount to NAV and Alan outlines why he sees strength in the business going forward.</p><p><br></p><p>Vela Technologies shares jumped this week as they announced the IPO of a portfolio company on the NASDAQ.</p>","author_name":"UK Investor Magazine"}